Hana names new vice president and chief medical officer

Dr Hagey will be responsible for all aspects of pre-clinical and clinical development for Hana’s portfolio of cancer therapeutic and supportive care candidates, reporting to Steven Deitcher, Hana’s president and CEO.

Dr Hagey joins Hana after eight years at Abbott Laboratories where she most recently served as the global project head overseeing clinical oncology drug development. In this role, she was responsible for managing the core clinical team as well as coordinating the expanded global project including discovery, toxicology, statistics and regulatory.

Dr Deitcher said: “We are excited to welcome Dr Hagey to our organization. Her extensive experience at Abbott Laboratories in the global clinical development of multiple oncology agents makes her the perfect addition to our already strong team. We look forward to her knowledge and leadership as a member of our management team as we advance multiple programs through clinical trials.”